The justified position of rosuvastatin in therapeutic practice


DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.47-53

N.P. Lyamina (1), A.V. Kosareva (2)

1) Moscow Scientific and Practical Center for Medical Rehabilitation, Restorative and Sports Medicine, Moscow, Russia; 2) Medicine AlphaStrakovanie LLC. Alpha – Health Center, Saratov, Russia

The article focuses on evidence-based knowledge on the use of lipid-lowering drugs. The target blood lipid indicators against the background of the treatment with statins are given, the choice of rosuvastatin for the category of patients who have had an acute cardiac event, myocardial infarction, acute cerebrovascular accident and/or transient ischemic attack is justified. The fundamental positions of international and Russian clinical guidlens on the management of patients after myocardial infarction and cerebral stroke for the prevention of complications, as well as for improving the prognosis, are discussed. The non-lipid pleiotropic effects of rosuvastatin are described. It was noted that the use of rosuvastatin does not create obstacles to its combined administration with antiplatelet agents and anticoagulants, which are necessary for patients of these categories.


For citations: Lyamina N.P., Kosareva A.V. The justified position of rosuvastatin in therapeutic practice. Farmateka. 2019;26(9):47–53. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.47-53 


About the Autors


Corresponding author: Nadezhda P. Lyamina, MD, Professor, Moscow Scientific and Practical Center for Medical Rehabilitation, Restorative and Sports Medicine, Moscow, Russia; e-mail: lyana_n@mail.ru
Address: 53, build. 1, Zemlyanoy Val Street, Moscow 105120, Russian Federation


Similar Articles


Бионика Медиа